Loading...
•
Dec 31, 2023
Balchem Q4 2023 Earnings Report
Balchem reported a solid Q4 2023, marked by record adjusted EBITDA and strong free cash flow, despite demand challenges in some areas. The Human Nutrition and Health segment achieved record sales and earnings.
Key Takeaways
Balchem Corporation reported Q4 2023 results with net sales of $228.7 million, net earnings of $26.6 million, adjusted EBITDA of $55.4 million, and free cash flow of $56.0 million. The Human Nutrition and Health segment had record sales and earnings.
GAAP net earnings increased by 24.5% year-over-year to $26.6 million.
Adjusted EBITDA increased by 5.4% year-over-year to $55.4 million.
Record free cash flow of $56.0 million, up 103.4% from the prior year quarter.
Record Human Nutrition & Health segment sales of $138.0 million, up 5.8% year-over-year, with record earnings from operations of $25.2 million, up 43.8%.
Balchem
Balchem
Balchem Revenue by Segment
Revenue by Segment
Human Nutrition & Health Revenue
CapyFin.comAnimal Nutrition & Health Revenue
CapyFin.comSpecialty Products Revenue
CapyFin.com Forward Guidance
Balchem is well positioned to deliver top and bottom line growth on a full year basis, while continuing to advance strategic growth initiatives.
Revenue & Expenses
Visualization of income flow from segment revenue to net income